Related Experiment Video
Updated: Jan 23, 2026

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
Published on: February 14, 2022
Blood Biomarkers of Heart Failure and Hypercoagulation to Identify Atrial Fibrillation-Related Stroke
Markus Kneihsl1, Thomas Gattringer1, Egbert Bisping2
1From the Department of Neurology (M.K., T.G., C.E., S.F.-H., S.E., C.H., B.B., B.P., K.N., F.F.).
Insights
N-terminal pro-brain natriuretic peptide (NT-proBNP) and hypercoagulation markers are linked to atrial fibrillation (AF)-related strokes. Elevated NT-proBNP levels can help identify cryptogenic stroke patients who may have occult AF.
Area of Science:
- Cardiology
- Neurology
- Biomarker Research
Background:
- Occult atrial fibrillation (AF) is a significant cause of cryptogenic stroke (CS).
- Prolonged cardiac monitoring for all CS patients is challenging.
- Biomarkers for heart failure and hypercoagulability may predict AF in CS patients.
Purpose of the Study:
- To investigate the association of NT-proBNP, D-dimer, and antithrombin-III (AT-III) with AF-related stroke.
- To evaluate these biomarkers for predicting AF detection in CS patients.
Main Methods:
- Prospective study of ischemic stroke patients over one year.
- Etiologic work-up for all patients; extended monitoring (≥72 hours) for CS patients.
- Blood biomarker levels (NT-proBNP, D-dimer, AT-III) measured within 24 hours of admission.
Main Results:
- AF-related stroke patients had higher NT-proBNP and D-dimer, and lower AT-III compared to non-cardiac stroke patients.
- NT-proBNP ≥505 pg/ml showed 93% sensitivity and 72% specificity for AF-related stroke.
- In CS patients, NT-proBNP ≥505 pg/ml predicted AF detection with 86% accuracy (98% negative predictive value).
Conclusions:
- NT-proBNP is associated with AF-related stroke and aids in identifying CS patients for monitoring.
- Lower NT-proBNP levels (<505 pg/ml) suggest a low likelihood of occult AF.
- Hypercoagulation markers showed a weaker association with AF-related stroke.
Abstract:
Background and Purpose- Occult atrial fibrillation (AF) causes a relevant proportion of initially cryptogenic stroke (CS), but prolonged rhythm monitoring is difficult to apply to all such patients. We hypothesized that blood biomarkers indicating heart failure (NT-proBNP [N-terminal pro-brain natriuretic peptide]) and hypercoagulability (D-dimer, AT-III [antithrombin-III]) were associated with AF-related stroke and could serve to predict the likelihood of AF detection in CS patients early on. Methods- Over a 1-year period, we prospectively applied a defined etiologic work-up to all ischemic stroke patients admitted to our stroke unit. If no clear stroke cause was detected (CS), patients underwent extended in-hospital cardiac rhythm monitoring (≥72 hours). Blood to determine biomarker levels was drawn within 24 hours after admission. Results- Of 429 patients, 103 had AF-related stroke. Compared with noncardiac stroke patients (n=171), they had higher NT-proBNP (1867 versus 263 pg/ml) and D-dimer levels (1.1 versus 0.6 µg/ml), and lower AT-III concentration (89% versus 94%). NT-proBNP ≥505 pg/ml distinguished AF-related from noncardiac stroke with a sensitivity of 93% and a specificity of 72%. D-dimer and AT-III cutoffs had lower sensitivities (61% and 53%) and specificities (58% and 69%) for AF-related stroke. Of all initially 143 CS patients, 14 were diagnosed with AF during in-hospital monitoring. The preidentified NT-proBNP cutoff ≥505 pg/ml correctly predicted AF in 12 of them (86%, negative predictive value: 98%), while D-dimer and AT-III cutoffs were noncontributory. Conclusions- This study supports the association of NT-proBNP and to a lesser extent of hypercoagulation markers with AF-related stroke. NT-proBNP seems helpful in selecting CS patients for immediate extended cardiac rhythm monitoring to detect occult AF whereby levels <505 pg/ml seem to have a high-negative predictive value.
Related Concept Videos
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Heart Failure I: Introduction
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Diuretics
Heart Failure V: Medical Management

